Iverheal 12 mg (Ivermectin)

Iverheal 12mg : Complete Medical Guide

Iverheal 12mg is a prescription antiparasitic tablet containing Ivermectin 12mg as its active ingredient, manufactured by Healing Pharma India Pvt. Ltd. It represents the highest-strength tablet in the Iverheal range and is indicated for the treatment of parasitic infections affecting the intestinal tract, skin, and eyes — including intestinal strongyloidiasis, onchocerciasis (river blindness), scabies, and lymphatic filariasis. 

Ivermectin, the active compound in Iverheal 12mg, belongs to the macrocyclic lactone class of broad-spectrum antiparasitic agents. It is included on the World Health Organization’s (WHO) List of Essential Medicines and is used in WHO-supported mass drug administration (MDA) programmes delivering hundreds of millions of treatments annually in tropical and subtropical endemic regions. The drug’s co-discoverers, Satoshi Ōmura and William C. Campbell, received the 2015 Nobel Prize in Physiology or Medicine for this discovery. 

Iverheal 12mg is the highest-strength oral formulation in the Iverheal range, prescribed primarily for patients with body weights of 65 kg and above — where a single 12mg tablet provides the correct weight-based dose for strongyloidiasis (200 mcg/kg) and onchocerciasis (150 mcg/kg). Dosage is always determined by the prescribing healthcare provider based on the patient’s body weight and clinical condition. 

Important: Iverheal 12mg is a prescription-only medication. It must not be used for self-medication and is not approved or recommended for the treatment of COVID-19 outside of formally supervised clinical research settings, as confirmed by the FDA and WHO. 

What is Iverheal 12mg? 

Iverheal 12mg is a brand-name oral tablet containing 12 milligrams of Ivermectin, produced by Healing Pharma India Pvt. Ltd., a GMP-compliant pharmaceutical manufacturer supplying regulated markets including the United States, the United Kingdom, Australia, and Southeast Asia. 

Ivermectin is a semisynthetic derivative of avermectin — a natural compound isolated from the soil bacterium Streptomyces avermitilis, first discovered in Japan in 1970 by Satoshi Ōmura and subsequently developed into a therapeutic agent by William C. Campbell and the team at Merck & Co. The compound comprises 80% 22,23-dihydroavermectin-B1a and 20% 22,23-dihydroavermectin-B1b, as confirmed by the FDA-approved Stromectol prescribing information. 

The 12mg strength is specifically designed for higher body weight patients where the weight-based dosing calculation requires a larger single tablet rather than multiple lower-strength tablets — improving dosing accuracy, simplifying administration, and promoting better treatment adherence. 

Iverheal 12mg belongs to the drug category of ectoparasiticides and anthelmintics (also classified within the antiparasitic therapeutic category), and is classified as a non-habit-forming medication. 

How Does Iverheal 12mg Work? 

Mechanism of Action 

Ivermectin exerts its antiparasitic activity through a precisely targeted mechanism, as described in the FDA-approved Stromectol prescribing label (revised September 2024). It binds selectively and with high affinity to glutamate-gated chloride ion channels (GluCl) present exclusively in the nerve and muscle cells of invertebrates — including parasitic worms and arthropod mites. This binding increases the permeability of the cell membrane to chloride ions, causing hyperpolarization of the nerve or muscle cell, resulting in paralysis and eventual death of the parasite. 

Critically, mammals do not possess glutamate-gated chloride channels, and Ivermectin does not readily cross the blood-brain barrier at therapeutic doses. This accounts for the drug’s selective toxicity to parasites while maintaining a comparatively favourable safety profile in humans. In vitro studies using human liver microsomes have confirmed that ivermectin does not significantly inhibit human CYP3A4, CYP2D6, CYP2C9, CYP1A2, or CYP2E1 metabolic activity at clinically relevant concentrations. 

Additionally, Ivermectin prevents adult female parasites from producing viable offspring, disrupting the parasite’s reproductive cycle and reducing long-term parasitic burden in the host. 

Pharmacokinetics 

Following oral administration, Ivermectin is absorbed from the gastrointestinal tract with a plasma half-life of approximately 16–18 hours in adults. Peak plasma concentrations are typically reached within 4 hours of ingestion. The drug and its metabolites are excreted almost exclusively via feces over approximately 12 days, with less than 1% of the administered dose eliminated through urine. Ivermectin is primarily metabolized in the liver via the CYP3A4 enzyme and also interacts with the P-glycoprotein (P-gp / ABCB1) drug transporter system — both of which are critical considerations for drug interactions. 

Bioavailability note: Ivermectin bioavailability increases substantially when taken with a high-fat meal. For strongyloidiasis and onchocerciasis, the FDA-approved label recommends administration on an empty stomach. For scabies, the CDC and dermatology experts recommend taking with food to enhance epidermal drug penetration and improve therapeutic outcomes — a key clinical distinction not mentioned in either competitor document. 

Uses of Iverheal 12mg 

Iverheal 12mg is prescribed to treat the following parasitic infections, supported by FDA approvals, WHO guidelines, and peer-reviewed clinical evidence: 

1. Intestinal Strongyloidiasis 

Caused by Strongyloides stercoralis — a parasitic roundworm capable of autoinfection (completing its life cycle entirely within the host) — strongyloidiasis can escalate to potentially fatal disseminated infection in immunocompromised individuals. Ivermectin is the first-line treatment of choice, with a reported cure rate of 64–100% following a single oral dose. The FDA-approved dose is 200 mcg/kg as a single dose on an empty stomach, with follow-up stool examinations required to confirm parasite eradication. 

2. Onchocerciasis (River Blindness) 

Caused by Onchocerca volvulus — a filarial worm transmitted by blackfly bites near fast-flowing rivers — onchocerciasis is a leading cause of preventable infectious blindness globally. Iverheal 12mg reduces microfilarial load in the skin and eyes, alleviating severe pruritus, subcutaneous nodules, and progressive vision loss. The drug does not kill adult worms residing within subcutaneous nodules (surgical excision may be considered to eliminate adult worms) but suppresses microfilarial production for 6 to 12 months per dose. In individual patient treatment, retreatment may be considered at intervals as short as 3 months; annual dosing is standard within WHO-supported MDA programmes. 

Critical warning — Loa loa co-infection: Ivermectin must NOT be used for onchocerciasis in patients co-infected with Loa loa due to the risk of potentially fatal encephalopathy in individuals with high Loa loa microfilarial counts. This co-infection risk is highest in patients from West and Central Africa. 

3. Scabies 

Scabies is caused by the mite Sarcoptes scabiei and presents with intensely pruritic skin lesions. While Ivermectin is not FDA-approved for scabies, it is widely used off-label and recognized by the CDC and international dermatology guidelines as an effective treatment. For classic scabies: two doses of 200 mcg/kg, each 7–14 days apart, taken with food per CDC recommendations. For crusted (Norwegian) scabies: combination therapy with topical agents is required, with oral Ivermectin given in 3, 5, or 7 doses (approximately on days 1, 2, 8 or extending to days 1, 2, 8, 9, 15, 22, 29) depending on infection severity, per CDC clinical care guidelines (2023). A 2025 systematic review and meta-analysis of 10 RCTs (1,105 patients) confirmed oral Ivermectin’s efficacy for scabies is comparable to topical benzyl benzoate. 

4. Lymphatic Filariasis 

Caused primarily by Wuchereria bancrofti and transmitted by mosquitoes, lymphatic filariasis is targeted for global elimination by the WHO by 2030 through the Global Programme to Eliminate Lymphatic Filariasis (GPELF). Ivermectin is used in annual MDA campaigns at a dose of 0.4 mg/kg, typically as part of a triple-drug regimen combining Ivermectin + Diethylcarbamazine + Albendazole (IDA) — which has demonstrated superior microfilarial clearance compared to dual-drug regimens in trials across Papua New Guinea, Haiti, Tanzania, and Nepal (2022–2024). 

5. Head Lice (Pediculosis Capitis) 

Oral Ivermectin is an effective option for head lice infestations resistant to topical treatments, acting by paralyzing lice and disrupting their feeding mechanism. A single dose is often sufficient, though a repeat dose after 7–10 days may be recommended based on clinical response. 

6. Cutaneous Larva Migrans 

Caused by hookworm larvae (primarily Ancylostoma braziliense) penetrating the skin from contaminated soil, this condition presents with characteristic serpiginous (winding track-like) skin lesions. A single dose of Ivermectin 200 mcg/kg, or alternatively albendazole 400 mg daily for 3 days, is the recommended treatment per clinical evidence. 

7. Mansonella Infections 

Iverheal 12mg is also used in infections caused by filarial parasites including Mansonella ozzardi, Mansonella perstans, and Mansonella streptocerca, transmitted through insect bites in endemic tropical regions. 

Available Strengths of Iverheal 

• Iverheal 3mg — for patients weighing 15–24 kg; also used in combination for other weight ranges 
• Iverheal 6mg — intermediate strength for patients in the 25–44 kg range 
• Iverheal 12mg — highest strength; standard single-tablet dose for patients in the 65–84 kg body weight range 

Dosage and Administration of Iverheal 12mg 

Iverheal 12mg dosage is individualized based on body weight and the specific parasitic condition being treated. The table below summarizes FDA-approved and clinically established weight-based dosage guidelines sourced from Drugs.com (January 2026) and the Stromectol prescribing label: 

Body Weight	Strongyloidiasis	Onchocerciasis	Scabies / Filariasis
15–24 kg	3 mg (1×3mg tab)	3 mg (1×3mg tab)	3 mg (1×3mg tab)
25–35 kg	6 mg (1×6mg tab)	6 mg (1×6mg tab)	6 mg (1×6mg tab)
36–50 kg	9 mg (1×9mg or 3×3mg)	9 mg	9 mg
51–65 kg	12 mg (1×12mg tab)	9 mg	12 mg
65–84 kg	12 mg (1×12mg tab)	12 mg (1×12mg tab)	12 mg (1×12mg tab)
≥ 85 kg	0.2 mg/kg	0.15 mg/kg	0.2 mg/kg

Strongyloidiasis: 0.2 mg/kg as a single oral dose on an empty stomach. For a 65–84 kg patient, a single 12mg tablet is the appropriate dose. 

Onchocerciasis: 0.15 mg/kg as a single oral dose every 12 months for MDA programmes; retreatment possible every 3 months for individual patients. 

Scabies (classic): 200 mcg/kg in two doses, 7–14 days apart, taken with food per CDC guidance. 

Crusted Scabies: 200 mcg/kg per dose, administered in 3, 5, or 7 doses (days 1, 2, 8; or days 1, 2, 8, 9, 15; or days 1, 2, 8, 9, 15, 22, 29) combined with a topical scabicide, depending on severity. 

Lymphatic Filariasis (MDA): 0.4 mg/kg orally once yearly, combined with diethylcarbamazine and albendazole (IDA triple-drug regimen). 

Immunocompromised patients (HIV/AIDS) with strongyloidiasis: Repeated dosing every 2 weeks may be required; monthly suppressive therapy in refractory cases. Complete cure may not be achievable in severely immunocompromised patients per Drugs.com clinical reference (2026). 

How to Take Iverheal 12mg 

• For strongyloidiasis and onchocerciasis: take on an empty stomach with a full glass of water (approximately 240 mL), at least 1 hour before a meal. 
• For scabies and head lice: take with food — CDC clinical care guidelines (2023) recommend this to enhance bioavailability and epidermal drug penetration for skin conditions. 
• Swallow the tablet whole. Do not crush, break, or chew it unless your healthcare provider has specifically advised this. 
• Adhere strictly to the dosing schedule and total number of doses prescribed by your healthcare provider. 
• Do not self-adjust doses or discontinue treatment prematurely without consulting your healthcare provider, as this may result in treatment failure or development of parasitic resistance. 

Missed Dose 

If a dose of Iverheal 12mg is missed, take it as soon as it is recalled — provided there is adequate time before the next scheduled dose. If the next dose is imminent, skip the missed dose and resume the regular schedule. Do not take two tablets simultaneously to compensate for a missed dose. For conditions requiring a single dose only (such as most strongyloidiasis cases), contact your healthcare provider if you miss the prescribed dose. 

Overdose 

In the event of an accidental overdose, discontinue the medication immediately and seek emergency medical attention or contact your nearest poison control centre without delay. Symptoms of Ivermectin overdose may include headache, dizziness, skin rash, vomiting, diarrhea, seizures, numbness, tingling sensations, difficulty breathing, and loss of consciousness. Your healthcare provider will manage presenting symptoms based on the amount ingested and clinical presentation. 

Precautions and Warnings 

Before initiating treatment with Iverheal 12mg, a thorough medical history must be disclosed to your healthcare provider. The following precautions require particular clinical attention: 

Loa loa Co-infection — Critical Warning 

This is the most serious contraindication associated with Ivermectin use. Patients who have lived in or travelled to West or Central Africa may be co-infected with Loa loa (African eye worm). In individuals with high Loa loa microfilarial counts — particularly above 30,000 mf/mL — administration of Ivermectin carries a documented risk of potentially fatal encephalopathy. Counts above 8,000 mf/mL warrant careful clinical management. Appropriate pre-treatment screening for Loa loa is essential for all at-risk patients before Iverheal 12mg is prescribed. 

Allergies 

Iverheal 12mg is contraindicated in patients with a known allergy to Ivermectin or to any inactive ingredient in the tablet formulation. Inform your healthcare provider of any history of allergic reactions before commencing treatment. Signs of a severe allergic reaction include skin rash, hives, facial or throat swelling, and difficulty breathing. Discontinue immediately and seek emergency medical care if anaphylaxis is suspected. 

Liver Disease 

Ivermectin is primarily metabolized in the liver via CYP3A4 enzymes. Patients with hepatic impairment or active liver disease should use Iverheal 12mg with caution and under close medical supervision, as impaired liver function may affect drug metabolism and increase the risk of adverse effects. Periodic liver function assessment may be appropriate. 

Kidney Disease 

While Iverheal 12mg is generally considered lower risk in mild to moderate renal impairment, patients with significant kidney disease should consult their healthcare provider before initiating therapy, as limited clinical data are available on Ivermectin use in severe renal impairment. 

Immunocompromised Patients (HIV/AIDS) 

Patients with compromised immune systems — including those living with HIV/AIDS or those on immunosuppressive therapy — may require repeated or prolonged treatment courses for strongyloidiasis due to impaired parasite clearance. In some cases, complete cure may not be achievable, necessitating long-term suppressive monthly therapy. Close clinical follow-up with stool examinations is essential in this population. 

Pregnancy 

Iverheal 12mg is generally not recommended during pregnancy. The safety of Ivermectin in pregnant women has not been established. NCBI Bookshelf evidence (2019) confirms Ivermectin is not approved for use in pregnant women. A 2024 clinical practice guideline for scabies published in the International Journal of Dermatology (Uzun et al., 2024) notes that while the CDC states the potential risk of Ivermectin in pregnant women is low, treatment with permethrin should be preferred due to limited pregnancy safety data. Ivermectin is proposed only as second-line treatment in the first trimester. Always consult a qualified healthcare provider before taking Iverheal 12mg during pregnancy. 

Breastfeeding 

According to the NIH LactMed database (last revised December 2024), Ivermectin is poorly excreted into breast milk after oral administration. Peak milk levels of approximately 15 mcg/L were detected at 4–12 hours post-dose, and amounts ingested by infants are small and would not be expected to cause adverse effects in breastfed infants over 7 days of age. A 2024 French Society of Dermatology guideline (Morand et al., British Journal of Dermatology) notes that Ivermectin may be considered as a first-line option for breastfeeding women treating scabies, with the recommendation to avoid application to the breast area. Nonetheless, consultation with a healthcare provider is advisable before using Iverheal 12mg during breastfeeding. 

Children 

Iverheal 12mg is approved for use in children weighing 15 kg or more. It is contraindicated in children weighing less than 15 kg, as safety has not been established in this weight group, per the NCBI Bookshelf clinical review and FDA prescribing guidance. Dosage is always weight-based. A Wellcome Trust-funded clinical trial (ClinicalTrials.gov NCT04332068) is currently evaluating the safety and pharmacokinetics of Ivermectin in children weighing 5–15 kg, which may expand its approved use in younger children in the future. 

Older Patients (Over 65 Years) 

Older patients may be more susceptible to the side effects of Iverheal 12mg due to age-related changes in hepatic and renal function, altered drug distribution, and potential polypharmacy. Iverheal 12mg should be used under close medical supervision in patients over 65 years of age, with careful assessment of co-administered medications and organ function. 

Asthma and Meningitis 

Iverheal 12mg is contraindicated in patients with a history of asthma or meningitis. These conditions represent absolute contraindications per clinical pharmacology references and prescribing guidance. 

Driving and Operating Machinery 

Iverheal 12mg may cause dizziness, fatigue, and loss of alertness in some individuals. Patients should refrain from driving, operating heavy machinery, or engaging in tasks requiring full cognitive alertness until the medication’s effects on their individual response have been established. 

Alcohol 

Concurrent use of alcohol during Iverheal 12mg therapy is not advisable. Alcohol significantly potentiates the central nervous system depressant effects of Ivermectin, intensifying dizziness, sedation, and risk of falls or accidents. Patients should abstain from alcohol throughout the treatment course. 

Special Dietary and Lifestyle Recommendations 

• Maintain good personal hygiene during treatment for intestinal parasitic infections — including regular handwashing before meals and after using the toilet — to prevent reinfection and transmission. 
• A balanced diet rich in fibre (whole grains, fruits, and vegetables) supports digestive health during treatment for intestinal strongyloidiasis. 
• Wash all clothing, bedding, and towels in hot water (above 50°C) if being treated for scabies to prevent environmental reinfection. 

Side Effects of Iverheal 12mg 

Like all medications, Iverheal 12mg may cause side effects in some individuals. Clinical evidence indicates that side effects occur in fewer than 4% of patients receiving Ivermectin for cutaneous parasitic conditions (Next Steps in Dermatology, 2025). The nature and severity of side effects vary according to the condition treated, body weight, dose administered, and individual patient response. 

Common (Mild) Side Effects 

The following mild side effects have been reported with Iverheal 12mg and generally resolve without medical intervention as the body adjusts to the medication: 

• Headache 
• Dizziness or lightheadedness 
• Nausea and loss of appetite 
• Vomiting 
• Diarrhea or stomach pain 
• Skin rash or mild itching 
• Fatigue or weakness 
• Swollen lymph nodes (lymphadenopathy) 
• Swelling or redness of the eyes 
• Muscle or joint pain 

Mazzotti Reaction — Onchocerciasis Treatment 

In approximately 10% of patients treated for onchocerciasis, a Mazzotti reaction may occur — an immunological response to the mass death of microfilariae. This is characterized by joint pain, swollen and tender lymph nodes, eye swelling, redness or pain, weakness, vision changes, itching, rash, and fever. These reactions typically appear within the first 4 days of treatment. They are usually self-limiting, but severe Mazzotti reactions may require oral hydration, recumbency, intravenous normal saline, and/or parenteral corticosteroids, per the Stromectol prescribing label (Merck/FDA, September 2024). 

Serious Side Effects — Seek Immediate Medical Attention 

The following serious adverse effects require prompt discontinuation of Iverheal 12mg and immediate emergency medical care: 

• Neurological effects: confusion, disorientation, seizures, difficulty walking or maintaining balance (ataxia), encephalopathy, or loss of consciousness 
• Severe respiratory effects: difficulty breathing, shortness of breath, or respiratory depression 
• Cardiovascular effects: low blood pressure (hypotension) causing dizziness, fainting, or lightheadedness; rapid or irregular heartbeat 
• Severe ocular effects: significant pain, bleeding within the eye, substantial vision changes, or sudden vision loss 
• Loss of bladder or bowel control: uncontrolled urination or bowel movements 
• Severe cutaneous reactions: extensive blistering, peeling, or signs of Stevens-Johnson syndrome 
• Hepatotoxicity: yellowing of the skin or eyes (jaundice), dark-coloured urine, or severe right upper quadrant abdominal pain 
• Extreme fatigue or coma: in severe cases of overdose or neurological toxicity 
• Severe neck or back pain 

Discontinue Iverheal 12mg immediately and seek emergency medical attention if any of the above serious side effects occur. 

Drug Interactions 

Ivermectin’s interaction profile arises primarily from its metabolism by CYP3A4 and its role as a substrate of the P-glycoprotein (P-gp / ABCB1) efflux transporter. According to drug interaction databases, Ivermectin has been documented to have interactions with 106 listed medications — including one major, many moderate, and several minor interactions (Factually.co clinical analysis, November 2025). Inhibitors or inducers of these pathways can raise or lower Ivermectin plasma levels and CNS exposure, respectively. 

Drug–Drug Interactions 

• Warfarin (anticoagulant) — MAJOR: The most clinically significant interaction. Post-marketing reports have confirmed that Ivermectin can increase warfarin’s anticoagulant effect, raising INR values and substantially increasing the risk of dangerous bleeding — even with a single dose of Iverheal 12mg. Patients on warfarin require close INR monitoring when Iverheal 12mg is introduced or discontinued. Warfarin dose adjustment may be necessary per RxList/Stromectol prescribing label (February 2025). 
• Benzodiazepines (e.g., alprazolam, diazepam) — MODERATE: Co-administration with Iverheal 12mg may enhance neurotoxicity and respiratory depression. CNS depressant effects are significantly amplified. Patients should be closely monitored for excessive sedation and respiratory compromise. 
• Barbiturates (e.g., phenobarbital, amobarbital) — MODERATE: Combined use may cause significantly increased CNS depression. Exercise caution and monitor closely during co-administration. 
• P-glycoprotein inhibitors (e.g., Quinidine, Ritonavir, Itraconazole) — MODERATE: Inhibition of P-gp allows Ivermectin to accumulate in the CNS, increasing the risk of neurological toxicity — including confusion, dizziness, ataxia, and in severe cases, seizures or coma. 
• CYP3A4 inhibitors (e.g., Erythromycin, Ketoconazole, Itraconazole) — MODERATE: These agents may reduce hepatic clearance of Ivermectin, elevating plasma concentrations and increasing the risk of adverse effects. 
• CYP3A4 inducers (e.g., Oxcarbazepine, Rifampicin) — MODERATE: May accelerate Ivermectin metabolism, potentially reducing therapeutic plasma concentrations and diminishing treatment efficacy. 
• HIV protease inhibitors (e.g., Ritonavir, Lopinavir, Atazanavir, Indinavir, Saquinavir) — MODERATE: May inhibit both CYP3A4 and P-gp, increasing Ivermectin blood levels and CNS penetration. Patients with HIV requiring Ivermectin should have this interaction specifically reviewed with their HIV specialist. 
• Mirabegron: May block enzyme activity involved in Ivermectin metabolism, increasing the risk of Ivermectin side effects. 
• Antiparasitic combinations (e.g., Albendazole, Mebendazole): When combined with Ivermectin (as in IDA triple-drug regimens for filariasis), liver stress is increased as all agents are processed hepatically. Close monitoring is recommended. 
• Valproic acid / Sodium oxybate: May potentiate CNS depressant effects of Ivermectin; use with caution. 

Drug–Food Interactions 

• Grapefruit juice: May inhibit intestinal CYP3A4 metabolism, potentially raising Ivermectin plasma levels. Avoid during treatment. 
• Alcohol: Potentiates CNS depressant effects; abstain for the duration of treatment. 
• High-fat meal (condition-specific benefit): For scabies and lice treatment, taking Iverheal 12mg with food increases bioavailability and improves epidermal penetration. For strongyloidiasis and onchocerciasis, food should be avoided at time of dosing. 

Drug–Disease Interactions 

• Liver disease: Impaired hepatic function may reduce CYP3A4-mediated Ivermectin metabolism, increasing drug accumulation and adverse effect risk. 
• Loa loa infection: Fatal encephalopathy risk in high microfilarial count patients (see Precautions). 

Always inform your healthcare provider of all prescription medications, over-the-counter drugs, herbal supplements, and recreational substances before commencing Iverheal 12mg. 

 Clinical Examination and Monitoring 

Prior to initiating Iverheal 12mg, your healthcare provider may recommend specific diagnostic tests to confirm the diagnosis and establish a monitoring baseline: 

Stool Examination 

For intestinal strongyloidiasis, stool microscopy is performed before treatment to confirm the presence of Strongyloides stercoralis larvae and repeated after treatment to verify eradication. Follow-up stool checks at 2–4 weeks post-treatment are standard practice. 

Skin Snip and Microfilariae Count 

For onchocerciasis, the microfilarial density in skin snips and ocular assessments is measured before and during treatment. A meaningful reduction in microfilarial count confirms treatment efficacy. Retreatment is indicated at 3-month intervals if counts do not improve satisfactorily. 

Pre-Treatment Loa loa Assessment 

In all patients from Loa loa-endemic regions (West and Central Africa), assessment of Loa loa microfilarial density is strongly recommended before prescribing Iverheal 12mg. Patients with counts above 8,000 mf/mL require careful clinical management; those with counts above 30,000 mf/mL should not receive Ivermectin without specialist oversight and an alternative management plan. 

Eye Examination 

Patients treated with Iverheal 12mg for ocular parasitic manifestations require serial eye examinations to monitor for treatment-related effects including uveitis, optic neuritis, or worsening ocular inflammation. Persistent ocular adverse effects may necessitate a change in therapeutic approach. 

Liver Function Tests 

In patients with pre-existing hepatic conditions or those requiring prolonged therapy, periodic liver function testing is advisable to monitor for hepatotoxicity and confirm adequate drug metabolism. 

 Storage Instructions 

• Store Iverheal 12mg below 30°C (86°F) in a cool, dry environment, away from direct sunlight, heat, and moisture. 
• Keep in the original packaging with the container tightly closed between uses. 
• Store out of reach of children and pets at all times. 
• Check the expiry date on the packaging before each use. Do not administer medication past its stated shelf life. 
• Do not dispose of unused or expired medication in wastewater or household refuse. Consult your pharmacist or local authority for guidance on safe pharmaceutical disposal. 

Frequently Asked Questions (FAQs) 

What is Iverheal 12mg used for? 

Iverheal 12mg is used to treat parasitic infections including intestinal strongyloidiasis, onchocerciasis (river blindness), scabies, lymphatic filariasis, cutaneous larva migrans, head lice, and Mansonella infections. It is the highest-strength Iverheal tablet and is prescribed primarily for patients in the 65–84 kg body weight range. It is not approved or recommended for COVID-19. 

Is Iverheal 12mg available over the counter? 

No. Iverheal 12mg is a prescription-only medication. It must not be used for self-medication. A valid prescription from a qualified healthcare provider is required before purchase or use. 

How does Iverheal 12mg work? 

Iverheal 12mg works by selectively binding to glutamate-gated chloride ion channels present only in invertebrate nerve and muscle cells. This causes hyperpolarization, leading to paralysis and death of the parasite. It also prevents adult female parasites from producing viable offspring. These channels do not exist in mammals, accounting for the drug’s selective toxicity to parasites at therapeutic doses. 

Can I take Iverheal 12mg on an empty stomach or with food? 

It depends on the condition being treated. For strongyloidiasis and onchocerciasis: take on an empty stomach with water (FDA-approved guidance). For scabies and head lice: take with food — CDC clinical guidelines recommend this to improve bioavailability and skin penetration for cutaneous conditions. Consult your healthcare provider for individualized guidance. 

How long does it take for Iverheal 12mg to work? 

Ivermectin is rapidly absorbed with peak plasma concentrations reached within approximately 4 hours of administration. Symptomatic relief — such as reduction in itching for scabies — may be noticeable within a few days. Complete parasite elimination and full clinical resolution may take 1–2 weeks depending on the condition and parasitic burden. 

Is Iverheal 12mg safe during pregnancy? 

The safety of Ivermectin in pregnancy has not been established. Iverheal 12mg is not approved for use in pregnant women. Clinical guidelines (International Journal of Dermatology, 2024) recommend permethrin as the preferred treatment option during pregnancy. Ivermectin may only be considered as a second-line option in the first trimester under close medical supervision when benefits clearly outweigh risks. 

Can I take Iverheal 12mg while breastfeeding? 

According to the NIH LactMed database (December 2024), Ivermectin is poorly excreted into breast milk, and the small amounts transferred to the infant are not expected to cause harm in infants over 7 days of age. A 2024 French Society of Dermatology guideline supports Ivermectin as a first-line option for scabies during breastfeeding, with the caution to avoid breast area application. Always consult your healthcare provider before using Iverheal 12mg while breastfeeding. 

Can children take Iverheal 12mg? 

Ivermectin tablets are approved for use in children weighing 15 kg or more. The 12mg tablet is appropriate for children and adults in the 65–84 kg weight range. Ivermectin is not approved for children weighing less than 15 kg, as safety in this group has not been established. 

What are the most important drug interactions with Iverheal 12mg? 

The most clinically significant interactions are: Warfarin (major — increases bleeding risk, requires INR monitoring), Benzodiazepines (enhanced CNS/respiratory depression), Barbiturates (increased CNS depression), P-gp inhibitors such as Quinidine and Ritonavir (CNS toxicity risk), CYP3A4 inhibitors including Erythromycin and Ketoconazole (elevated Ivermectin levels), and HIV protease inhibitors (dual pathway interference). Always disclose all medications to your healthcare provider before starting Iverheal 12mg. 

Is Iverheal 12mg habit-forming? 

No. Iverheal 12mg is not habit-forming. It does not have any known dependency or addiction potential. 

References

• Drugs.com. (Medically reviewed by Melisa Puckey, BPharm. Updated August 2025). Ivermectin: Uses, Dosage, Side Effects, Warnings. https://www.drugs.com/ivermectin.html
• Drugs.com. (Updated January 2026). Ivermectin Dosage Guide + Max Dose, Adjustments. https://www.drugs.com/dosage/ivermectin.html
• RxList / Cunha JP. (Last updated February 2025). Stromectol (Ivermectin): Side Effects, Uses, Dosage, Interactions, Warnings — based on FDA-revised prescribing label, September 2024. https://www.rxlist.com/stromectol-drug.htm
• U.S. Food & Drug Administration. (Revised September 2024). Stromectol (Ivermectin) Tablets Prescribing Information. Merck Sharp & Dohme LLC. https://www.accessdata.fda.gov/drugsatfda_docs/label/2022/050742s030lbl.pdf
• Centers for Disease Control and Prevention (CDC). (Updated December 2023). Clinical Care of Scabies. https://www.cdc.gov/scabies/hcp/clinical-care/index.html
• NIH LactMed Database. (Last revised December 15, 2024). Ivermectin — Drugs and Lactation Database. National Library of Medicine. https://www.ncbi.nlm.nih.gov/books/NBK501375/
• Uzun S, et al. (2024). Clinical practice guidelines for the diagnosis and treatment of scabies. International Journal of Dermatology. https://onlinelibrary.wiley.com/doi/10.1111/ijd.17327
• Morand A, Weill A, Miquel J, et al. (2024). Management of scabies in children under 15 kg and pregnant or breastfeeding women: recommendations supported by the Centre of Evidence of the French Society of Dermatology. British Journal of Dermatology, 191(6), 1014–1016. https://academic.oup.com/bjd/article/191/6/1014/7717190
• NCBI Bookshelf. (2019). Ivermectin for Parasitic Skin Infections of Scabies: A Review of Comparative Clinical Effectiveness, Cost-Effectiveness, and Guidelines. Canadian Drug Agency. https://www.ncbi.nlm.nih.gov/books/NBK545083/
• MedFinder. (Updated June 2026). Ivermectin Drug Interactions: What to Avoid. https://www.medfinder.com/blog/ivermectin-drug-interactions-what-to-avoid-what-to-tell-your-doctor
• Medical News Today. (Updated September 2025). Ivermectin interactions: Alcohol, supplements, and more. https://www.medicalnewstoday.com/articles/drugs-ivermectin-oral-tablet-interactions